NEWSTIER

Amylyx Pharmaceuticals shares are trading higher after the company announced it will reveal its topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026. |

Amylyx Pharmaceuticals To Announce Phase 3 LUCIDITY Trial Topline Results For Avexitide In Post-Bariatric Hypoglycemia On August 18 At 8:00 a.m. ET | 4:01 PM EDT, August 17, 2026 (Benzinga Newswire) Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will announce topline results…

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 | CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will announce topline results from…

ExxonMobil Awards ~$1.1B Contracts For Upstream Equipment Supporting Rovuma LNG Phase 1 Development In Cabo Delgado | 3:47 PM EDT, August 17, 2026 (Benzinga Newswire) https://corporate.exxonmobil.com/locations/mozambique/mozambique-newsroom/exxonmobil-mozambique-and-area-4-coventurers-award-over-1-…

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™ | WASHINGTON--(BUSINESS WIRE)-- Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of…

EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction. -- Barrons.com | EyePoint's experimental treatment for an advanced eye disease yielded what management called "clinically meaningful results" in a late-stage trial. Shares were pacing toward their worst day on record an…

Update: argenx Shares Rise After Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study | 02:30 PM EDT, 08/17/2026 (MT Newswires) -- (Updates with reporting date in the first paragraph, and the latest stock move in the headline and first paragraph) argenx (ARGX) shares rose more than 16% in Mond…

EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction. -- Barrons.com | EyePoint's experimental treatment for an advanced eye disease yielded what management called "clinically meaningful results" in a late-stage trial. Shares were pacing toward their worst day on record an…

EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. | EyePoint's experimental treatment for an advanced eye disease yielded what management called "clinically meaningful results" in a late-stage trial. Shares were pacing toward their worst day on record anyway. The small…

iGov Technologies Selected to Advance to Phase 2 of U.S. Marine Corps EWGIR Prototype Program | TAMPA, Fla.--(BUSINESS WIRE)-- iGov Technologies, Inc., a leading provider of advanced federal tactical communications solutions, has been selected to advance to Phase 2 of the U.S. Marine Corps’ Electro…

Argenx’s Next Blockbuster? Stock Jumps 12% After Phase 3 Myositis Trial Hits Key Goal | 9:22 AM EDT, August 17, 2026 (Benzinga Newswire) Argenx SE (NASDAQ:ARGX) stock jumped about 12% in Monday’s premarket trading after the company reported positive topline results from its Phase 3 ALKIVIA study. T…

Galmed Pharmaceuticals Announces Results From Pre-Clinical Study Of Combination Of Aramchol And Xtandi For Prostatic Cancer; New Data Demonstrated That A Combination Of Aramchol With Enzalutamide Resulted In Three- To Four-Fold Increase In Cell Death Compared With Enzalutamide As A Single Agent | 9…

Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia | Phase 1b/2a clinical trial assessing safety and efficacy of LTX-001 in adults with schizophrenia initiated Financing advances LTX-001 through initial readout from Ph…

Connext Completes Enrollment in Phase 2 Trial of CNT201 in Dupuytren's Contracture | - All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive data could support expansion of CNT201 into Peyronie's disease and…

Artelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies | 8:56 AM EDT, August 17, 2026 (Benzinga Newswire) The Patent Claims are for the Intende…

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies | The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 S…

EyePoint shares are trading lower after the company announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU. The primary endpoint of change from baseline in best corrected visual acuity versus 2 mg aflibercept on-label control was not achieved in the full dataset…

HUTCHMED shares are trading higher after the company announced high-level results from the SAFFRON Phase III trial. |

OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors | — ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual syst…

EyePoint Misses Primary Goal in Phase 3 Wet AMD Trial of Duravyu; Shares Drop Pre-Bell | 07:57 AM EDT, 08/17/2026 (MT Newswires) -- EyePoint (EYPT) said Monday its Phase 3 Lugano trial testing Duravyu in patients with wet age-related macular degeneration failed to achieve its primary endpoint. The…

Mesoblast shares are trading higher after the company announced it completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain. |

United Therapeutics Completes Enrollment in Phase 3 PPF Trial of Tyvaso | 07:41 AM EDT, 08/17/2026 (MT Newswires) -- United Therapeutics (UTHR) said Monday that its Phase 3 TETON-PPF study evaluating nebulized Tyvaso in patients with progressive pulmonary fibrosis has fully enrolled 754 participant…

AstraZeneca And Daiichi Sankyo Report DESTINY‑Lung04 Phase III Trial Results; ENHERTU Improves Progression‑Free Survival Versus Standard Of Care In HER2‑Mutant NSCLC | 7:39 AM EDT, August 17, 2026 (Benzinga Newswire) AstraZeneca and Daiichi Sankyo’s ENHERTU is the first and only HER2-directed medic…

Radiopharm Theranostics Schedules An FDA End-Of-Phase 2 For October 1, 2026, To Align On The Design Of A Pivotal Phase 3 Trial To Evaluate RAD101 In Patients With Suspected Recurrence Of Brain Metastases Following Radiotherapy | 7:36 AM EDT, August 17, 2026 (Benzinga Newswire) RAD101 is the Company…

argenx shares are trading higher after the company announced topline results from the ALKIVIA Phase 3 study met its primary endpoint. |

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases | RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 meeting with t…

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial | AstraZeneca and Daiichi Sankyo’s ENHERTU is the f…

AstraZeneca And HUTCHMED’s Savolitinib, In Combination With TAGRISSO, Delivers Significant Survival Benefits In SAFFRON Phase III EGFRm Lung Cancer Trial | 7:10 AM EDT, August 17, 2026 (Benzinga Newswire) First global Phase III trial to show significant progression-free and overall survival benefit…

EyePoint Announces Topline Results From LUGANO, First Pivotal Phase 3 Clinical Trial For DURAVYU For Treatment Of Wet Age-Related Macular Degeneration | 7:04 AM EDT, August 17, 2026 (Benzinga Newswire) – DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad ho…

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD | – DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experien…

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis | Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed earl…

Update: argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study | 05:01 AM EDT, 08/17/2026 (MT Newswires) -- (Updates with reporting date in the first paragraph and the latest stock move in the last paragraph) argenx (ARGX) said Monday a phase 3 study evaluating its experimental drug,…

argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study | 04:25 AM EDT, 08/17/2026 (MT Newswires) -- argenx (ARGX) said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met main goal. The company said the patients treated with the d…

Mesoblast Completes Patient Treatment in Phase 3 Trial of Chronic Low Back Pain | 04:13 AM EDT, 08/17/2026 (MT Newswires) -- Mesoblast (MESO) said Sunday it has completed patient treatment in a phase 3 trial of its experimental rexlemestrocel-L for chronic low back pain associated with degenerative…

AstraZeneca Discontinues Phase 3 Lung Cancer Trial for Volrustomig Combination | 03:35 AM EDT, 08/17/2026 (MT Newswires) -- AstraZeneca (AZN) is stopping a phase 3 trial evaluating volrustomig in combination with chemotherapy for patients with metastatic non-small cell lung cancer, the company said…

Daiichi Sankyo And AstraZeneca's Enhertu Shows Significant PFS Improvement As First-Line HER2 Mutant NSCLC Treatment In DESTINY-Lung04 Phase 3 Trial | 2:54 AM EDT, August 17, 2026 (Benzinga Newswire) Daiichi Sankyo and AstraZeneca’s Enhertu is the first and only HER2 directed medicine to improve pr…

Reported Sunday, Mesoblast Completes Patient Treatment In Pivotal Phase 3 MSB-DR004 Trial Of Rexlemestrocel-L For Chronic Low Back Pain, Enrolling 350 Patients |

Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial | Daiichi Sankyo and AstraZeneca’s Enhertu is the first and onl…

Argenx's Efgartigimod Becomes First Phase 3 Therapy To Show Statistically Significant, Clinically Meaningful Improvement In IMNM, A Subtype With No Approved Treatment | 1:22 AM EDT, August 17, 2026 (Benzinga Newswire) Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in th…

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis | Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and susta…